Share with others who have ER-/PR-/HER2- breast cancer.
Posted on: Dec 26, 2019 05:28PM
Immunotherapy for Early-Stage Triple-Negative Breast Cancer: Understanding What Appear to Be Conflicting Results
December 19, 2019
Results from two studies on using the immunotherapy medicines Tecentriq or Keytruda along with chemotherapy to treat early-stage triple-negative breast cancer before surgery suggested that Keytruda offered benefits while Tecentriq did not. Read more...